scAAV8OTC
301OTC01
Phase 2 gene_therapy completed
Quick answer
scAAV8OTC for Ornithine Transcarbamylase (OTC) Deficiency is a Phase 2 program (gene_therapy) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx Pharmaceutical
- Indication
- Ornithine Transcarbamylase (OTC) Deficiency
- Phase
- Phase 2
- Modality
- gene_therapy
- Status
- completed